An American company has announced on Sunday that it has conducted clinical studies of the Egyptian market of the genetic fourth pattern of the hepatitis C virus in six centers for liver diseases.
The new drug, which the company says has a 100 percent cure rate, is known in the United States and Europe as Viekira Pak. It is taken without Interferon.
The company said it would announce the result of the study at the end of this year.
It said the new drug does not contain Sovaldi, a previous hepatitis C drug that prevents the virus cells from dividing.
It said hepatitis C has six different genetic patterns numbered from 1 to 6, of which the fourth is the most spread in Egypt and the Middle East.
Edited translation from Al-Masry Al-Youm
